Scarborough Health Network (SHN) has played an essential role in a massively important international study that is changing the way doctors treat atrial fibrillation, a common heart rhythm disorder affecting millions worldwide. The study, published in the prestigious New England Journal of Medicine (NEJM), has already captured headlines across major media outlets for its practice-changing findings.
Under the leadership of SHN cardiologists, SHN Research Institute contributed the largest number of patients to this global trial.
What the Study Found
For years, patients undergoing catheter ablation for atrial fibrillation were routinely prescribed blood thinners to prevent stroke. While effective, these medications carry a significant risk of bleeding complications. This new study provides definitive evidence that low-dose Aspirin can safely replace blood thinners for many patients after ablation.
For patients, the impact is huge: no longer needing blood thinners means avoiding common symptoms associated with these medications — fewer bleeding risks and more freedom in daily life.
Why this Matters for Scarborough
Atrial fibrillation is not just a global issue, it is a local one. Many Scarborough residents live with heart disease, and this research offers hope for safer, simpler care. By enrolling the largest patient group in the study, SHN ensured that voices from our community were part of shaping this important advancement.
“I am very proud of the fact that SHN and patients in Scarborough were able to contribute to answering a very important question that is relevant to many who suffer from heart diseases here in Scarborough and around the world,” said Dr. Kevin Kuo, Vice President of Research at SHN.
“This achievement underscores our growing reputation as a centre for cutting-edge research and innovation, and reflects our commitment to improving health outcomes for the diverse communities we serve.” This milestone reflects SHN’s growing role in research that changes lives. SHN Research Institute is actively supporting more studies like this, ensuring that Scarborough remains at the forefront of medical innovation.